Hap Trading, LLC Iovance Biotherapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$3.3 - $8.89 $331,320 - $892,556	100,400 New	100,400 $88.1 Million
Q2 2021 Aug 11, 2021	SELL	$16.33 - $33.07 $2.08 Million - $4.22 Million	-127,600 Reduced 75.24%	42,000 $137,000
Q1 2021 May 14, 2021	SELL	$28.67 - $52.59 $2.89 Million - $5.3 Million	-100,700 Reduced 37.25%	169,600 $141,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $7.09 Million - $12.7 Million	252,800 Added 1444.57%	270,300 $1.89 Million
Q3 2020 Nov 13, 2020	SELL	$27.75 - $36.3 $47,175 - $61,709	-1,700 Reduced 8.85%	17,500 $41,000
Q2 2020 Aug 10, 2020	SELL	$27.21 - $41.0 $1.81 Million - $2.72 Million	-66,400 Reduced 77.57%	19,200 $15,000
Q1 2020 May 08, 2020	BUY	$19.54 - $38.85 $275,514 - $547,785	14,100 Added 19.72%	85,600 $465,000
Q4 2019 Feb 11, 2020	BUY	$17.95 - $29.41 $1.28 Million - $2.1 Million	71,500 New	71,500 $248,000
Q2 2018 Aug 13, 2018	SELL	$12.45 - $16.95 $623,745 - $849,195	-50,100 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$8.1 - $19.5 $405,810 - $976,950	50,100 New	50,100 $19,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.